Understanding the immune response in COVID-19 patients in intensive care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the immune response kinetics in adult patients hospitalized in intensive care due to SARS-CoV-2 infection. By collecting blood samples within the first 24 hours of ICU admission, researchers will create a biocollection to better understand the inflammatory response and potential immunosuppression associated with COVID-19. The study seeks to fill the knowledge gap regarding the immune dynamics of critically ill COVID-19 patients, which could inform future treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Man or woman aged 18 or over,
2. Hospitalization in intensive care for Sars-Cov-2 pneumopathy,
3. First hospitalization in intensive care unit,
4. Positive diagnosis of SARS-CoV2 infection carried out by PCR or by another approved method in at least one respiratory sample,
5. Sampling in the first 24 hours after admission to intensive care unit (D0 / D1) feasible,
6. Patient or next of kin who has been informed of the terms of the study and has not objected to participating.

Exclusion Criteria:

1. Pregnant or lactating woman,
2. Person placed under legal protection,

Where it's running

• Hôpital Pierre Wertheimer
  Bron, France Recruiting
• Hôpital Edouard Herriot
  Lyon, France Recruiting
• Hôpital Edouard Herriot
  Lyon, France Recruiting
• Hôpial de la Croix Rousse
  Lyon, France Recruiting
• Hôpital Lyon Sud
  Pierre-Bénite, France Recruiting
• Hôpital Gabriel Montpied
  Clermont-Ferrand, France Not yet recruiting

Study contacts

• Principal investigator: Fabienne VENET — Hospices Civils de Lyon
• Study coordinator: Fabienne VENET
• Email: fabienne.venet@chu-lyon.fr
• Phone: 4 72 11 97 46

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vaccine formulations containing mRNA-1273 and mRNA-1283 to see if they boost immunity and remain safe

  This study tests whether two mRNA vaccines that target SARS-CoV-2 can safely generate an immune response in older adults and people with risk factors.

  Recruiting at 5 sites Phase 4 ModernaTX, Inc. · Overland Park, Kansas and 4 other locations · NCT07863635

• Vaccine study to test mRNA-1283 in children and infants

  A vaccine study will test two dose levels of mRNA-1283 in kids from 6 months to under 12 years to see which dose works best, using mRNA-1273 as a comparison.

  Recruiting at 12 sites Phase 2 ModernaTX, Inc. · Ontario, California and 30 other locations · NCT07808697

• Genomic changes of Klebsiella pneumoniae and Enterobacter cloacae in ICU patients over time

  This study tests how the gut bacteria Klebsiella pneumoniae and Enterobacter cloacae evolve over time in adults in ICUs.

  Recruiting University Hospital, Caen · Caen · NCT07744321

• Secutrelvir for high-risk COVID-19 patients who are not in hospital

  This study tests whether secutrelvir can help nonhospitalized teens and adults with COVID-19 who are at high risk of getting worse.

  Recruiting at 38 sites Phase 3 Shionogi Inc. · Coral Gables, Florida and 50 other locations · NCT07743580

• Kisspeptin to measure GnRH neuron function in people with and without post-COVID-19 syndrome

  We will give one intravenous kisspeptin dose and take frequent blood samples to see if people with post-COVID-19 syndrome have different GnRH/LH hormone responses than people who had COVID but did not develop long COVID.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07224490

• Using blood cell ratios and procalcitonin to predict outcomes for adults with sepsis in the ICU

  This project will test whether routine blood measures—neutrophil-to-lymphocyte-and-platelet ratio, procalcitonin, and total white blood cell count—can help predict outcomes for adults with sepsis in the intensive care unit.

  Recruiting Ain Shams University · Cairo · NCT07200817

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.